Clinical Trial Update: A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007) [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating MK-6194 for non-segmental vitiligo has been terminated, and results were posted on 2026-03-17.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• MK-6194

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-segmental Vitiligo | Phase 2 | Status: TERMINATED | Results posted: 2026-03-17